SARCOMAS: Edited by Jean-Yves BlayImmunotherapy in sarcoma: combinations or single agents? In whom?Dufresne, Armelle; Brahmi, MehdiAuthor Information Medical Oncology Department, Centre Leon Berard, Lyon, France Correspondence to Armelle Dufresne, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France. Tel: +33 4 69 85 61 46; e-mail: email@example.com Current Opinion in Oncology: July 2020 - Volume 32 - Issue 4 - p 339-343 doi: 10.1097/CCO.0000000000000651 Buy Metrics Abstract Purpose of review First clinical trials investigating immune check point (ICP) inhibitors in patients with sarcoma, regardless histological or molecular subtypes did not demonstrate any prolonged benefit. To maximize the chance of benefit from immunotherapy, recent strategies explore the combination of treatments and aim to improve identification of responsive histological subtypes. Recent findings Combination of several ICP inhibitors tends to increase toxicity and efficacy. Mechanisms of synergistic action remain unclear. Combination of ICP blockade with tyrosine kinase inhibitor increases efficacy in specific histological subtypes already identified as sensitive to each drug separately. The role of the combination is not established yet. Several ongoing trials assess the combination of ICP blockade with chemotherapy or radiotherapy. ICP blockade seems highly effective in some selected histological subtypes like alveolar soft part sarcoma, chordoma, malignant rhabdoid tumor, and angiosarcoma. Encouraging preliminary results need to be confirmed in larger cohorts and biological mechanisms that sustain this efficacy should be further explored. Adoptive cell therapy seems very promising in synovialosarcoma. Summary Significant efforts are underway to efficiently develop immunotherapy in patients with sarcoma and better characterize patients who would benefit the most from it. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.